Catheter Precision, Inc. (VTAK) - 10-Q Summary for Period Ended June 30, 2024
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for the period ended June 30, 2024. Catheter Precision, Inc. is a medical technology company focused on cardiac electrophysiology (EP) following a 2023 merger with "Old Catheter." The company discontinued its legacy DABRA laser business to focus on the VIVO System (3D cardiac mapping) and the LockeT suture retention device. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $175,000 | $181,000 |
| Net Loss | $(6,895,000) | $(67,976,000) |
| Net Loss Per Share (Basic & Diluted) | $(9.19) | $(169.70) |
| Cash and Cash Equivalents (End of Period) | $16,000 | $7,410,000 |
| Net Cash Used in Operating Activities | $(3,639,000) | $(16,900,000) |
| Total Assets | $26,261,000 | $30,736,000 |
| Total Liabilities | $11,944,000 | $9,543,000 |
| Stockholders' Equity | $14,317,000 | $21,193,000 |
Debt and Liquidity: As of June 30, 2024, the company held $650,000 in notes payable due to related parties (8% interest, maturing August 30, 2024). Cash reserves were critically low at $16,000.
Material Changes vs. Prior Period
- Revenue: Decreased slightly by $6,000 (3.3%) year-over-year. This was due to lower VIVO System sales, partially offset by the first commercial sales of the LockeT device ($38,000).
- Net Loss: Significantly improved (reduced) by approximately $61 million compared to the prior year. The 2023 period included a one-time goodwill impairment charge of $60.9 million, which did not recur in 2024.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses decreased by $6.3 million year-over-year, primarily due to reduced legal fees related to the 2023 merger and lower stock-based compensation adjustments.
- Non-Cash Items: The 2024 period included a $1.6 million expense related to the change in fair value of royalties payable, whereas the 2023 period included a $4.6 million gain in the same category.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year following the report date. Cash on hand ($16,000) is insufficient to fund operations through August 2025.
- Liquidity Actions: The company obtained $850,000 in bridge loans subsequent to June 30, 2024. Total short-term loans due August 30, 2024, amount to $1.5 million. The company is actively seeking additional capital through debt or equity transactions.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including lack of segregation of duties, errors in royalty accounting, and revenue recognition timing. A remediation plan is underway.
- Reverse Stock Split: A 1-for-10 reverse stock split was approved by shareholders and became effective on July 15, 2024. Financial statements have been retrospectively adjusted.
- Product Outlook: The company is expanding its sales force and expects CE Mark approval for LockeT in the second half of 2024.
Key Facts for Investor Verification
- Cash Runway: Verify the status of the $1.5 million in related-party notes due August 30, 2024, and whether the company has secured additional financing to meet this obligation.
- Going Concern Status: Confirm if the company has raised sufficient capital to remove the "substantial doubt" regarding its ability to continue operations.
- Revenue Concentration: Note that three customers represented 92% of revenue for the quarter ended June 30, 2024.
- Internal Control Remediation: Monitor progress on fixing material weaknesses in financial reporting, specifically regarding royalty calculations and revenue recognition.
- Related Party Transactions: Review the terms of the bridge loans provided by the CEO and affiliates, including interest rates and maturity dates.